Clinical outcomes and treatment patterns in adults with FLT3-ITDmut+ acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the US and Canada
Acute myeloid leukemia (AML) is considered a genetically heterogeneous disease, with different AML subtypes associated with distinct outcomes.1 Internal tandem duplications of the FMS-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) are present in approximately 25% of patients with AML and are associated with higher rates of relapse and shorter overall survival.2,3 In these patients, allogeneic hematopoietic cell transplantation (alloHCT) represents a potentially curative treatment option.4
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Bhavik J. Pandya, Linda J Burns, Tao Wang, Bin Xie, Maelys Touya, James Spalding, Alana Block, Gaston Kuperman, Christopher Young Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Burns | Canada Health | Genetics | Hematology | Leukemia | Transplants